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Abstract
Background:  P-glycoprotein belongs to the family of ATP-binding cassette proteins which
hydrolyze ATP to catalyse the translocation of their substrates through membranes. This protein
extrudes a large range of components out of cells, especially therapeutic agents causing a
phenomenon known as multidrug resistance. Because of its clinical interest, its activity and
transport function have been largely characterized by various biochemical studies. In the absence
of a high-resolution structure of P-glycoprotein, homology modeling is a useful tool to help
interpretation of experimental data and potentially guide experimental studies.
Results:  We present here three-dimensional models of two different catalytic states of P-
glycoprotein that were developed based on the crystal structures of two bacterial multidrug
transporters. Our models are supported by a large body of biochemical data. Measured inter-
residue distances correlate well with distances derived from cross-linking data. The nucleotide-free
model features a large cavity detected in the protein core into which ligands of different size were
successfully docked. The locations of docked ligands compare favorably with those suggested by
drug binding site mutants.
Conclusion: Our models can interpret the effects of several mutants in the nucleotide-binding
domains (NBDs), within the transmembrane domains (TMDs) or at the NBD:TMD interface. The
docking results suggest that the protein has multiple binding sites in agreement with experimental
evidence. The nucleotide-bound models are exploited to propose different pathways of signal
transmission upon ATP binding/hydrolysis which could lead to the elaboration of conformational
changes needed for substrate translocation. We identified a cluster of aromatic residues located at
the interface between the NBD and the TMD in opposite halves of the molecule which may
contribute to this signal transmission.
Our models may characterize different steps in the catalytic cycle and may be important tools to 
understand the structure-function relationship of P-glycoprotein.
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Background
ATP-binding cassette (ABC) proteins form a large protein
family in living organisms that carry various substrates
across cell membranes. There are 48 ABC transporters in
humans and mutations in many have been linked to
genetic disorders[1,2].
The P-glycoprotein (P-gp), product of the mdr1 gene in
humans, is one of these ABC transporters that extrudes a
large range of structurally diverse compounds out of cells,
a feature that has been described as poly-specificity[3,4].
It is the most extensively studied ABC transporter and can
be used to understand the function of this important class
of proteins. The overexpression of P-gp is associated with
a multidrug resistance phenotype in various forms of can-
cer[5], which is a major barrier to the successful treatment
of these diseases.
The vast majority of ABC transporters require energy in
the form of ATP to translocate their ligands across the cell
membrane. They require a minimum of four domains:
two transmembrane domains (TMDs) form the ligand
binding site and two nucleotide-binding domains
(NBDs) bind and hydrolyze ATP to proceed to the sub-
strate translocation. Two subtypes of ABC transporters can
be defined on the basis of the direction of the transport
reaction: ABC importers only present in prokaryotes and
ABC exporters. Like many eukaryotic ABC transporters P-
gp comprises all four domains in a single polypeptide
chain. It is composed of 1280 residues, organized as two
homologous halves (which are 43% identical in human
P-gp) each with 6 transmembrane (TM) segments and a
cytosolic NBD. Several helices of the TM domains have
been proposed to accommodate the binding site(s) and
consequently are believed to form the pathway through
which the substrates cross the membrane. On the other
hand the NBDs couple the energy associated with ATP
binding and hydrolysis to drug transport[6]. The NBDs
are better conserved than the TMDs and share several
common motifs including the Walker A and B motifs that
are found in other ATPases and the ABC signature that is
unique to the family.
The P-gp mediated-transport mechanism has been exten-
sively studied but remains controversial. Briefly it is
believed[4,7] that the transport cycle is initiated by sub-
strate binding in the TM domains of P-gp, which increases
the ATP affinity for the protein. After binding and/or
hydrolysis of a first ATP molecule in one of the NBDs sev-
eral restructurings occur in the TM domains of the protein.
This conformational change allows the release of the drug
to the extracellular medium. P-gp returns to its original
configuration possibly after hydrolysis of a second ATP
molecule. The protein is then reset for another cycle. Two
alternative models for the transport cycle of P-gp[7] are
currently proposed and the most significant difference is
in the nature of the mechanism that drives the drug from
a high affinity site to a low affinity site in the TMDs. In one
model[4] the formation of a closed NBD dimer provokes
conformational changes that are transmitted to the drug
binding site. Two sequential ATP hydrolysis events reset
the P-gp molecule. Other models[8] require either one[9]
or two[8] hydrolysis reactions to supply the efflux of the
drug and the resetting of the protein for another cycle.
The considerable body of biochemical data obtained on
ABC transporters has been more recently complemented
by X-ray structures. At present several complete structures
are available. All are of bacterial origin: five are ABC
importers (BtuCD, ModBC-A, HI1470/1, MalFG/K,
MetNI) [10-16] and two are drug exporters (SAV1866 and
MsbA) [17-19]. In ABC importers the four domains exist
as separate units whereas bacterial exporters are half trans-
porters with one TMD and one NBD per polypeptide
which function as a homo or hetero-dimer. These struc-
tures as well as genomic analysis and TM predictions[20]
suggest that the domain organization of the importers is
not shared by that of the exporters and that the TMD
topology is also different.
Together biochemical data and structure determination
can help in understanding the mechanism of the ABC
exporters. However crystallization of membrane proteins
to obtain direct information on three-dimensional (3D)
structure is still a difficult task and no atomic-level struc-
ture of P-gp is available so far. Only structural information
has been obtained at low resolution by electron micros-
copy (EM)[21,22]. In the absence of a high resolution
structure for P-gp use of molecular modeling has been rec-
ommended in order to generate 3D models to sustain
interpretation of experimental data[23] and potentially
guide experimental studies. Several 3D models of the
nucleotide-free protein were first published and most of
them were either completely or remotely based on
retracted former MsbA crystal structures[24]. Only two
studies clearly stated that models constructed exclusively
on MsbA dimeric structures were incompatible with cross-
linking data on P-gp[25,26]. To unravel this problem, in
one of these studies, the helices in the TMDs initially
modeled from MsbA monomer structure were largely
reshuffled using additional restrained potentials, defined
from cross linking data, in molecular dynamics simula-
tions[26]. However the construction process of this model
lacked experimental data to properly describe the
NBD:TMD interfaces and the relative position of the TM
helices in each P-gp half.
The publication of the structures of SAV1866[17,18],
which has a topology akin to that of P-gp prompted new
3D models of the nucleotide-bound conformation of P-gpBMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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to be constructed [27-29]. These structures have been
determined in presence of ADP and AMP-PNP. They are
very similar and feature a drug extrusion chamber open to
the extracellular side. New crystallographic studies of ABC
exporters trapped in different conformational states are
needed to reveal changes along the catalytic cycle, f.i.
upon substrate translocation and ATP hydrolysis. Revised
MsbA structures trapped in different conformations have
been very recently made available: two nucleotide-bound
structures and two in absence of nucleotide[19]. The two
nucleotide-bound structures possess an outward-facing
conformation very similar to SAV1866 structures. The
nucleotide-free structures determined at a quite low reso-
lution feature two strongly different inward (intracellu-
lar)-facing conformations.
We present here four 3D models of P-gp describing two
different states along the catalytic cycle using the recent X-
ray structures of bacterial ABC exporters as templates. The
models elaborated by comparative modeling are con-
fronted to a large number of available experimental data.
Interactions between conserved residues describing path-
ways from the ATP binding site towards the TMDs are
examined to propose potential ways of transmitting a sig-
nal upon ATP binding or hydrolysis. Likewise conserved
residues are pinpointed in the regions which could possi-
bly be involved in the hinge binding motion suggested by
the different crystallographic structures allowing the tran-
sition between the different conformational states. The
interaction of compounds with P-gp is clearly a complex
process. One of the nucleotide-free 3D models is used to
dock several ligands in the central cavity harbored by the
TM domains. The geometry of interaction of the ligands is
examined and compared with the experimental data.
Methods
Selection of templates
A PSI-BLAST search[30] identified two bacterial ABC
exporters homologous to human P-gp. One is SAV1866
from S. aureus whose structures were solved in complex to
ADP[17] (PDB code 2HYD) and to AMP-PNP[18] (PDB
code 2ONJ). The other is MsbA, a lipid flippase, which is
available in two nucleotide-bound conformations (MsbA
from S. typhimurium; PDB codes 3B60 and 3B5Z) and in
two nucleotide-free conformations (MsbA from E. coli or
V. cholerae; PDB codes 3B5W and 3B5X)[19]. The nucle-
otide-free structures include only the Cα positions.
Sequence alignment
The sequences of human P-gp, S. aureus SAV1866, V. chol-
erae MsbA, S. typhimurium MsbA and E. coli MsbA can be
accessed at the Universal Protein Ressource (UniProt).
The percentage of sequence identity between P-gp and
SAV1866 or MsbA ranges from 27% to 32% (sequence
similarity is between 47% and 53%). Such percentages of
identity make these templates potential candidates to
elaborate 3D models of P-gp by comparative modeling.
The similarity however varies noticeably for the cytosolic
and transmembrane domains. The NBDs have sequence
identity of about 50% and the TMDs have sequence iden-
tity ranging between 15% and 23% (sequence similarity
between 30% and 43%). A multiple-sequence alignment
of these protein sequences was performed using Clus-
talW[31] (see Figure 1).
Trans-membrane domain prediction
Trans-membrane domain predictions were performed on
the P-gp sequence using HMMTOP[32]. The results of
these predictions which are reported on the ClustalW
alignment (Figure 1) show a good correspondence with
the trans-membrane segments of SAV1866 and MsbA
determined with PDBTM[33].
Model building
The multiple-sequence alignment was used as a basis to
construct the models. It underwent only little modifica-
tions within two short sequence regions: one at the C-ter-
minus of TM1 and the second at the residue pairs
Asp498–Glu499 in the N-terminal half and Glu1143–
Glu1144 in the C-terminal half. These changes were moti-
vated by the sequence alignment generated from the struc-
tural superposition of the crystallographic structures of
SAV1866 and S. typhimurium MsbA, in presence of AMP-
PNP.
Four models describing P-gp in two different catalytic
states were built using MODELLER 9v1[34]. Two models
of P-gp in presence of nucleotides were constructed upon
the structure of SAV1866 (PDB code: 2HYD) and the
structure of S. typhimurium MsbA (PDB code: 3B60)
respectively. Two models of P-gp in absence of nucleotide
were built upon either the structure of V. cholerae MsbA
(PDB code: 3B5X) or that of E. coli MsbA (PDB code:
3B5W). Each run produced ten different conformations
that were optimized with the variable target function
method employing methods of conjugate gradients and
molecular dynamics with simulated annealing. Only the
five models with the lowest potential energy were kept for
further analysis. Measured distances were calculated on
each model and averaged.
MODELLER builds models by satisfying different types of
spatial restraints which include homology-derived
restraints, stereochemical restraints obtained from
CHARMM22 force field and statistical preferences for
dihedral angles and non bonded distances obtained from
a representative set of protein structures. Models are thusBMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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not constructed differently whether one resorts to all
heavy atom or Cα atom only templates.
The positioning of one ATP molecule in each active site
was performed as follows: the template structure either
the SAV1866 or MsbA structure bound to AMP-PNP was
superposed onto the corresponding 3D model. The nitro-
gen atom in AMP-PNP was changed into oxygen in a coor-
dinate PDB file containing the 3D model. The sodium ion
close to AMP-PNP in the SAV1866 structure was also
changed into magnesium (the MsbA structure complexed
to AMP-PNP contains no ion). Finally 100 steps of steep-
est descent minimization of the whole system were per-
formed. The RMSD calculated before and after
minimization is about 0.3 Å for ATP and 0.1 Å for all Cα
atoms.
Ligand docking
Docking was performed with the AutoDock program (ver-
sion 4.00)[35]. Eight independent docking runs were car-
ried out for each ligand starting from randomly generated
initial conformations of the ligand. We used the genetic
algorithm in AutoDock to perform the global search,
completed with a local search, as it has been shown that it
gives efficient sampling.
The binding zone was defined as a cube whose length was
set to 30 Å. It enclosed the whole central cavity. The grid
spacing was equal to 0.375 Å. The population size was set
to 50 and the maximum number of generations to 27000.
The rate of crossover was 80% and the maximum number
of individuals that automatically survive was 1. The muta-
tion rate was fixed to 2%.
Multiple sequence alignment Figure 1
Multiple sequence alignment. Multiple sequence alignment of V. cholera, S. typhimurium, E. coli MsbA, SAV1866 and human 
P-gp used to generate the 3D models of P-gp. The predicted trans-membrane regions are grayed.BMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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The initial 3D structures of the ligands were generated
with the CORINA program[36]. The computed
Gasteiger[37] and Kollman united-atom atomic partial
charges[38] were ascribed for the ligands and the protein
respectively.
Results
Modeling of P-gp conformational states
In each model three P-gp fragments were not modeled
because they lacked template. These three regions are: the
first thirty N-terminal amino-acids, the first extracellular
loop (ECL1) and the sixty amino-acids of the linker which
connects the N-terminal to the C-terminal halves of P-gp.
The alignment of various mammalian homologues of
human P-gp reveals that the amino-acid sequences of
these three regions are not chiefly conserved which sug-
gests that they are not essential for the function of P-gp.
This has been experimentally demonstrated for two of
these three fragments. Deletions of the glycosylation sites
located in ECL1 have shown that this region is not essen-
tial for the activity of P-gp as a multidrug exporter[39].
ECL1 was modeled as two helices in a model derived from
an EM study[21]. However, because of the low resolution
of the EM structure and of the weak helical propensity of
this fragment observed in a secondary structure predic-
tion, we decided not to model this loop. As for the linker
region, mutation or deletion experiments have proven
that only structural flexibility is required to ensure ATP
hydrolysis and drug transport[40].
Four models of P-gp (Figure 2) were built. Two models
describe a nucleotide-bound state. One of the two models
was built using as a template the structure of MsbA S. typh-
imurium complexed to AMP-PNP (PDB code: 3B60). In
contrast to ATP, AMP-PNP can not be hydrolyzed thus
MsbA has been trapped in a conformation that describes
a state resulting from ATP binding. The other model was
constructed using the SAV1866 structure determined in
presence of ADP (PDB code: 2HYD). A more recent struc-
ture of SAV1866 in complex with AMP-PNP (PDB code:
2ONJ) shows no significant conformational change with
the ADP-bound structure suggesting that this structure
also mimics a post ATP-binding state. We used the ADP-
bound structure of SAV1866 as a template because of its
better resolution.
The other two models describe P-gp in different nucle-
otide-free conformations. One model was built using as a
template the Vibrio cholera MsbA nucleotide-free structure
(PDB code: 3B5W) and the other using the E. Coli nucle-
otide-free structure (PDB code: 3B5X).
The two nucleotide-bound models share the same out-
ward-facing conformation whereas the two nucleotide-
free models depict two different conformations: an open
and a closed inward-facing conformation (see Figure 2).
The stereochemistry of the four models was assessed with
PROCHECK[41]. The Ramachandran plots show a high
percentage of the residues in the allowed regions: 99.7%
and 98.3% for the nucleotide-bound models built with
the SAV1866 and MsbA S. typhimurium structures respec-
tively. 98% and 96.2% of the residues in the open and
closed nucleotide-free models respectively are located in
allowed regions of the Ramachandran plot.
The dimensions of the nucleotide-bound models are
roughly 65 × 75 × 135 Å and the lengths of the TM helices
range between 50 to 80 Å. The 12 TM helices exhibit a
two-fold symmetry. These geometrical observations are
consistent with the highest resolution images of P-gp
bound to a nonhydrolyzable analog of ATP obtained by
EM[21]. More recently, Lee et al.[22] have analyzed the
structure of cysteine-free human P-gp from two-dimen-
sional crystals in lipid monolayer in the presence or
absence of various nucleotides. Their EM analysis predicts
the nucleotide-free structure to be distinctly different from
the nucleotide-bound one. The large conformational
movement observed between our nucleotide-bound and
nucleotide-free models agrees with these observations.
Figure 2A illustrates the molecular surface of the models
colored according to the physico-chemical nature of the
residues. Amino-acids contacting the lipid membrane
form a hydrophobic belt round the TMDs. In contrast, the
surfaces of the NBDs, the intracellular (ICLs) and extracel-
lular (ECLs) loops are more hydrophilic. A significant
number of aromatic (Tyr, Trp) and positively charged res-
idues (Arg, Lys) are located at the borders of the mem-
brane embedded region with their side chain oriented
toward the outside of the structure. It has been proposed
that these residues interact favorably with the polar heads
of lipids[42]. This distribution of residues on the molecu-
lar surface of the models supports the quality of the align-
ments.
The structures of ABC exporters disclose that in contrast to
ABC importers the TMD helices extend far beyond the
membrane interface into the cytoplasm (see Figure 2B).
Pertaining to these long ICLs are four short helices, also
named coupling helices[43], roughly oriented parallel to
the membrane that contact the NBDs. The striking feature
that was revealed by the X-ray structure of SAV1866 and
confirmed recently by the MsbA structures is that the sec-
ond short helix in ICL2 and in ICL4 crosses over and asso-
ciates with the NBD of the other monomer. The
importance of this cross-over motif is even more high-
lighted in the two nucleotide-free structures of MsbA[19].
Cross-linking experiments performed between residues
located in NBD1 and ICL4 or NBD2 and ICL2 [44,45]
confirm the pertinence of this domain arrangement in P-
gp (see Figure 2B). Our models are consistent with these
data since the distances between the Cα of the residuesBMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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A. Molecular surface representation of the 3D models Figure 2
A. Molecular surface representation of the 3D models. (a) Nucleotide-bound model built with the SAV1866 template. 
(b) Nucleotide-bound model built with the S. typhimurium MsbA template. (c) Closed and (d) Open nucleotide-free models 
built with the V. cholerae MsbA and the E. coli MsbA templates respectively. The surface of hydrophobic residues (Ala, Leu, Val, 
Ile, Pro, Phe and Met) are colored in yellow. Other residues are colored in blue. The two red lines indicate the position of the 
lipid polar heads in the cellular membrane. B. View of a nucleotide-bound conformation of P-gp. The N-terminal half is 
highlighted: the three extracellular loops (ECL) are colored in pink (ECL1 is truncated (see text)), the two long intracellular 
loops are colored in yellow with the small coupling helices in pale green. The 6 trans-membrane helices are colored in blue 
(TM1), red (TM2), gray (TM3), orange (TM4), cyan (TM5) and green (TM6) and the nucleotide binding domain (NBD) is 
colored in magenta. The intracellular segment of TM1 and TM6 are depicted in light blue. All these segments are labeled from 
the N-terminus to the C-terminus.BMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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involved in the cysteine mutagenesis range from 8.5 Å to
11.5 Å (see Table 1). Furthermore, the relative arrange-
ment of ICL4 or ICL2 relative to the NBDs in our models
agrees with several cross-linking data in CFTR[46], which
shares the same topology and exhibits 36% of sequence
similarity with P-gp. In CFTR, Phe508 of NBD1 can cross-
link to several residues in ICL4 and Cys276 in ICL2 forms
a cross-link with residues of the C-terminal NBD (see
Table 1). The aligned sequences of the Q-loop regions and
of these ICL portions feature about 50% similarity
between P-gp and CFTR.
Table 1 compares the inter-residue distances measured in
all four models and the experimental distances derived
from cross-linking data. The measured distances between
NBD:NBD and NBD:TMD residues are in better agree-
ment than those involving TMD:TMD residue pairs. Some
of the distances are comparable in the nucleotide-bound
and the nucleotide-free structures whereas others are only
in accord with data in one of the two states. The cross-link-
ing distances tend to disagree more in studies probing the
central cavity within the TMDs. This can be explained by
the huge flexibility within P-gp and, in particular within
its TMDs which may cause a potential problem in cross-
linking studies. Indeed at room temperature cysteines
may sometimes come closer and then crosslink even
though they are relatively far apart in most of the sampled
conformations. Measured distances between TM2–TM8,
TM1–TM11, TM2–TM11, TM5–TM8, TM6–TM7 however
agree reasonably well with experimental cross-linking
data.
Nucleotide-bound models
The two constructed models adopt very similar conforma-
tions (rmsd = 1.9 Å, calculated on the Cα superposed in
an alignment of the structures) in agreement with the
structural similarity of the two templates. The RMSD
between the modeled P-gp structures and their corre-
sponding templates is 0.5 and 0.3 Å for SAV1866 and
MsbA structures respectively. The NBD dimer closes the
cytoplasmic side of the trans-membrane domain. The
bundle of trans-membrane helices is closely packed near
the NBDs while it is wide-open to the extracellular space
shaping an 'outward-facing' conformation[17]. We posi-
tioned two ATP molecules in each model using the loca-
tion of the nucleotides in the crystallographic structures of
their respective template (see Methods). This shows that
the tightly bound NBD dimer occludes the two nucleotide
molecules.
In both models, the nucleotide-binding pocket displays
no opening that would allow entry of an ATP molecule
from the solvent. Likewise, these nucleotide-bound mod-
els do not feature any potential entry through which sub-
strates could enter the transporter either laterally from the
membrane leaflet or from the cytosol. These findings sug-
gest that conformational changes should occur to permit
the access of the substrate and of the nucleotide molecule.
Structural interpretation of NBD mutants
In our models each ATP-binding site is formed by the res-
idues of the Walker A, Walker B and Q-loop from one
NBD and is closed by residues of the signature motif from
the other NBD (Figure 3). Both NBDs are then associated
in a head to tail fashion to form two binding pockets with
the nucleotide sandwiched between the Walker A and the
signature motif that face each other. This feature is sus-
tained by cross-linking experiments (Table 1), which
show that residues of WalkerA can be linked to residues of
the signature in the opposite NBD[47,48].
Our models show that Lys433 and 1076 in the WalkerA
motifs are located at a close distance of the ATP phos-
phates (the distance between the Nζ and Pβ or Pγ atoms
is about 4.5 Å). This would explain that mutations of
these lysine residues[49,50] disrupt ATP hydrolysis and
even affect ATP binding to various degrees.
Tyr401 and Tyr1044 in NBD1 and NBD2, respectively,
named A-loop[51], are well conserved and appear to be
essential for ATP-binding[51,52]. Their equivalent tyro-
sine residues in hamster P-gp were shown to lie close to
the adenine ring of a bound ATP in a photolabelling
study[53]. In both models, each tyrosine forms a stacking
interaction with the ATP adenine ring suggesting its
importance for the nucleotide affinity.
The glutamate in the Walker B motif, often referred to as
the 'catalytic carboxylate'[54], is also well conserved
across species. In our models, Glu556 and Glu1201 are
located near the ATP γ phosphate group (the distance
between the Oε and the Pγ atoms is 5.1 Å.). Several muta-
tions have demonstrated that both the chemical nature
and the length of the side chain at these positions are
essential for the binding and release of the nucleotide[55]
as well as for the catalysis of hydrolysis[55]. Asp555 and
Asp1200 are also part of the Walker B motifs. The muta-
tion of these residues to asparagine abolishes both basal
and drug stimulated ATP hydrolysis[56]. These two resi-
dues are also thought to participate to the Mg2+ bind-
ing[57]. In our models, the side chains of Asp555 and
Asp1200 are oriented toward the phosphate Pγ (The dis-
tance between the Oδ and the Pγ atoms is 6.6 Å).
The Q-loop[58] contains a well conserved glutamine resi-
due at position 475 and 1118 in NBD1 and NBD2 respec-
tively. It is located between the WalkerA and signature
motifs in an otherwise less conserved region. In our mod-
els, the residues of the Q-loop participate both to the
nucleotide binding and to the NBD:TMD interface. (theBMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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Table 1: Comparison of inter-residue C -C  distances
Residues Region Cα-Cα distances (Å) Exp. cross-linking (Å) Ref.
Nucl.-bound* Nucl.-bound** Closed-nucl.-free Open-nucl.-free
NBDs
S1072/L531 WalkerA/Signature 9.9 10.5 41.0 65.6 5.5–15 [47]
S1072/S532 6.8 7.5 37.7 63.2
G1073/L531 7.6 8.3 37.2 68.1
G1073/S532 5.4 6.3 33.9 65.8
G1073/G533 7.9 8.9 30.5 65.2
C1074/L531 10.8 10.8 34.9 65.4
G1075/L531 10.4 10.6 37.5 66.7
S429/L1176 10.0 10.6 40.1 66.5
G430/L1176 7.6 8.4 36.3 68.7
G431/L1176 10.9 10.9 34.1 66.6
G432/L1176 10.5 10.7 36.9 68.1
C431/L1176 10.9 10.9 34.1 66.6 [48]
L531/C1074 10.8 10.8 34.9 65.4
G427/C1074 WalkerA/WalkerA 31.0 30.9 13.5 56.8 [63]
L439/C1074 36.6 35.7 19.4 64.6
C431/C1074 33.4 33.1 7.9 54.0 [64]
NBD:TMD
L443/S909 8.6 9.8 14.2 9.2 6–16 [44]
S474/R905 8.9 9.0 8.4 11.4
A266/F1086 8.6 10.0 13.8 9.7 5.5–15 [45]
Y490/V907
(CFTR: F508/L1065)
7.9 9.1 12.5 9.2 [46]
Y490/L910
(CFTR: F508/F1068)
7.2 6.9 8.7 8.0
Y490/T911
(CFTR: F508/G1069)
9.5 8.2 11.5 9.5
Y490/F916
(CFTR: F508/F1074)
9.3 10.2 10.6 10.3
E493/T911
(CFTR: V510/G1069)
10.6 8.6 8.3 10.0
V478/T906
(CFTR: W496/T1064)
6.5 7.4 8.2 9.6
F480/V907
(CFTR: M498/L1065)
10.8 10.8 11.7 11.7
R547/T911
(CFTR: K564/G1069)
11.0 9.9 15.4 13.0
G269/Q1107
(CFTR: C276/Q1280)
8.4 10.4 13.5 11.8
G269/A1111
(CFTR: C276/K1284)
8.5 10.1 13.4 11.2BMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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distance between the Oε and the Pγ atoms is 4.3 Å.). In P-
gp, the most obvious effect of mutation of this glutamine
is to reduce stimulation of ATP hydrolysis by drugs[59].
Nucleotide-free models
Our two models show that the bundle of trans-membrane
helices is closed on the extracellular side and open
towards the cytosol (Figure 2A). These conformations fea-
ture an 'inward-facing' state. The RMSD between the mod-
eled P-gp structures and their corresponding templates is
1.7 Å for the open nucleotide-free model and 0.5 Å for the
closed nucleotide-free model. In the model built upon the
closed nucleotide-free structure, the NBDs establish a
loosely tight dimer, though they do not form an ATP
TMDs
A80/T74
(MsbA: F56/F56)
TM2/TM8 33.0 34.5 22.8 12.9 [68]
M68/Y950 TM1/TM11 9.5 11.8 15.7 10.8 [94]
M68/Y953 7.8 13.0 16.9 11.7
M68/A954 8.1 12.8 17.9 13.5
M69/A954 10.9 15.2 20.8 16.1
M69/F957 10.3 15.4 20.5 15.4
V133/G939 TM2/TM11 5.6 5.7 12.0 7.0 [95]
C137/A935 6.7 6.9 10.5 7.6
117YYS119/555GCF557# 9.1–15.7 9.6–15.6 16.5–22.0 9.7–15.5 6–16 [25]
S222/I868 TM4/TM10 41.4 46.1 42.1 34.3 9–25 [96]
S222/G872 41.7 45.0 41.5 34.3
L227/S993 TM4/TM12 32.8 34.9 37.8 31.4 5.5–15 [97]
V231/S993 32.4 33.1 34.2 30.3
W232/S993 29.4 29.9 30.7 28.5
A233/S993 28.1 28.6 29.6 25.4
I235/S993 30.9 30.9 30.6 29.7
L236/S993 27.3 27.4 27.2 26.6
N296/G774 TM5/TM8 5.6 5.8 11.9 7.1 [98]
I299/F770 7.7 7.9 11.5 9.5
I299/G774 8.8 10.3 16.7 11.9
G300/F770 5.6 6.9 12.8 7.7
317GTT319/753NLF755# 9.8–15.2 9.2–14.0 19.0–23.8 9.4–14.6 6–16 [25]
I306/I868 TM5/TM10 36.3 41.0 34.6 32.1 13–25 [96]
I306/G872 36.7 40.4 34.9 33.4
I306/T945 TM5/TM11 33.5 37.0 30.0 33.2
I306/V982 TM5/TM12 24.4 31.3 24.4 19.0
I306/G984 27.8 31.1 26.1 21.5
A295/S993 23.2 24.1 24.2 22.3 5.5–15 [97]
I299/S993 22.6 24.5 26.3 21.2
L339/F728 TM6/TM7 6.7 10.7 18.1 19.2 20–25 [99]
P350/V874 TM6/TM10 32.5 33.2 34.5 29.9 5.5–15 [97]
P350/E350 29.4 30.1 31.0 27.9
P350/M876 28.2 28.6 29.7 24.8
L339/I868 30.0 37.1 30.4 23.3 13–25 [96]
L339/G872 32.0 37.7 29.9 23.7
L332/Q856 36.0 41.3 33.5 21.4 10–17
P350/G939 TM6/TM11 22.9 23.6 25.3 19.2 5.5–15 [97]
L339/T945 27.5 33.1 24.5 21.5 20–25 [100]
L339/F942 26.7 31.2 22.1 21.0 25 [96]
L332/L975 TM6/TM12 21.9 27.3 17.6 7.8 5.5–15 [99]
F343/M986 16.4 20.0 18.6 21.6 [101]
G346/G989 20.2 23.7 23.5 26.4
P350/S993 17.3 19.5 25.4 32.1
F343/V982 16.8 23.3 20.5 18.9 10 [99]
L339/V982 15.6 25.1 20.7 15.1 16–25
L339/A985 19.6 26.9 23.2 19.1 20–25 [96]
L332/L976 22.0 28.2 17.8 11.2 9–13
Distances calculated in the nucleotide-bound (nucl.-bound) and nucleotide-free (nucl.-free) models are compared with distances derived from 
experimental cross-linking data determined in P-gp, CFTR and MsbA. Calculated distances in the range of the experimental distances are shown in 
bold and underlined. (*: SAV1866 template and **: S. typhimurium MsbA template; #: Cross-linking is observed for each residue of the triplet)
Table 1: Comparison of inter-residue C -C  distances (Continued)BMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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sandwich as in the nucleotide-bound state. In the model
built using the open nucleotide-free structure, the dimer is
disrupted. The capacity for ABC exporters to sample a
large conformational space is supported by spectroscopic
data on LmrA[60], a structural bacterial homologue of P-
gp that can functionally substitute P-gp and shares its sub-
strate specificity[61]. High motional flexibility within the
TM domain of LmrA was also reported by ATR-FTIR spec-
troscopy and 1H-2H exchange[62].
In contrast to the nucleotide-bound model the nucle-
otide-free conformations feature openings that would
allow the entry of a nucleotide molecule to the active site.
The closed nucleotide-free model depicts the two Walker
A motifs facing each other. This feature is in agreement
with cross-linking experiments[63,64] showing that
Cys1074 in NBD2 can be cross-linked to Cys431,
Gly427→Cys or Leu439→Cys in NBD1 (Table 1). The
open nucleotide-free model portrays the two Walker A
motifs at a distance of about 50 Å producing a wide
entrance to the interior of the TM domain. This could
allow the access of transported substrates, some of which
are quite bulky. Such a large opening has been reported by
EM structural studies on other ABC transporters like
Mdl1[65] and YvcC[66]. More importantly a very recent
ESR study on MsbA[67] reports that the closing of the
chamber towards the cytoplasmic side occurs through
very large movements and that the NBDs are very far apart
in the absence of nucleotide as in the open MsbA X-ray
structure. The open nucleotide-free structure is also con-
sistent with a cross-linking distance between residues
located at the extracellular side of TM1[68] (see Table 1).
Ligand binding
One of the intriguing features of P-gp is that it recognizes
and transports a large variety of substrates. Though
numerous studies have attempted to identify mutations in
P-gp that affect the recognition and transport of substrates
the localization of the binding site(s) is still an open ques-
tion. Here we use the closed nucleotide-free model to
locate residues known to be involved in drug binding.
Strikingly all residues which have been identified as affect-
ing the drug specificity [69-81] are confined mainly in the
TM domain embedded in the outer membrane leaflet (see
Figure 4). Almost all residues face the large central cavity.
A few of these facing residues however are shielded from
the central pore. In particular, Ser222 in TM4 is hidden by
TM5 and TM6 and Ile868, Ala871 and Gly872 of TM10
are shielded by TM11 and TM12.
In order to further assess the accuracy of the model we per-
formed the docking of a number of P-gp ligands. The
scope is double: first to verify whether the central cavity
can accommodate the different ligands and second to ana-
lyze the binding site for each ligand and identify the con-
tacted residues. Docking was carried out on verapamil,
rhodamineB, colchicine and vinblastine, which differ by
their size, topology and their chemical functionalities.
The volume in which the ligands were docked was cen-
tered on the geometric center of the residues experimen-
tally identified to alter drug specificity (see listed residues
in the legend of Figure 4). This volume was taken large
enough to enclose the large central cavity that runs
between the borders with the cytosol and the extracellular
medium. Nevertheless most of the positions of the differ-
ent ligands are found in the TM domain located in the
outer membrane leaflet portion. Vinblastine however
which is the biggest of the docked ligands occupies a
region which runs from the outer leaflet to the middle part
of the inner leaflet and one of the docked poses of rhod-
amineB is found closer to the TM domain located in the
inner leaflet. Interestingly all docked poses for each ligand
are found to interact with residues which have been exper-
imentally identified to bind a specific ligand (Figure 4 and
Table 2). The docked poses for verapamil roughly sample
two locations, one of which presents several contacts with
experimental binding residues. The docked positions of
rhodamineB are the most spread of all ligands with how-
ever one more populated cluster. Colchicine exhibits two
groups of poses one of which, most populated, makes
NBD closed dimmer Figure 3
NBD closed dimmer. Ribbon representation (top view 
from the membrane) of the NBD closed dimer of one of the 
nucleotide-bound models in presence of two ATP molecules 
depicted as sticks. The N-terminal NBD (light blue) and the 
C-terminal NBD (light pink) are associated in a head to tail 
fashion. Each ATP binding pocket is formed by the A-loop 
(yellow), the Walker A motif (dark blue), the Walker B motif 
(black) and the Gln of the Q-loop depicted in orange from 
one NBD and is closed by the Signature motif colored in red 
from the other NBD.BMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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interactions with experimentally identified residues. The
poses of vinblastine cluster mainly into one group. Each
pose fills almost completely the upper part of the central
cavity which narrows towards the extracellular side. The
drug binding site in our model shows that none of the lig-
ands because of their size and of the distance between the
binding site residues can bind at the same time all its
experimentally identified residues (Figure 4).
Conformational changes: signal transmission and 
triggering
Binding and/or hydrolysis of ATP induce conformational
changes that are transmitted from the NBDs to the TMDs.
The nature and amplitude of these conformational
changes remain elusive though the recent X-ray structures
of ABC exporters trapped in different states together with
the numerous biochemical data[82] suggest a possible
role of different portions of the protein in the transmis-
sion of a signal following ATP binding.
In this section, we analyze our models to propose poten-
tial transmission pathways produced by ATP binding and/
or hydrolysis. The residues involved in the transmission
mechanism of ABC exporters are likely to be conserved
across species. So to isolate them, the amino-acid
sequence of each P-gp half was aligned separately with the
sequences of 200 homologous ABC exporters using Con-
Surf[83].
Starting from the nucleotide-bound models, so as to take
advantage of the presence of a nucleotide molecule in
each binding pocket, we analyzed the interactions made
by each nucleotide with neighboring residues identified
by ConSurf as conserved residues having a potential func-
tional role. In what follows we describe the potential
pathways starting from the N-terminal and the C-terminal
NBDs. For sake of clarity, the residues and protein frag-
ments identified starting from the C-terminal NDB are
given in curly brackets.
We detected two main ways of transmission, which could
originate from residues interacting either with adenine or
with the γ phosphate group of ATP (Figure 5).
In both the N- and C-terminal halves, the adenine makes
a hydrogen bond with a conserved Asp164 {Asp805} of
the small coupling helix of ICL1 {ICL3}. Transmission
could also arise through the interactions of adenine with
Tyr444 {Tyr1087} whose side chain hydrogen bonds
both to adenine and to Asp164 of ICL1 {Asp805 of ICL3}.
Furthermore, Tyr444 {Tyr1087} makes an edge-to-face
interaction with Tyr401 {Tyr1044}, the A-loop, strongly
conserved across species, which, itself, stacks to the ade-
nine. Interestingly Leu443 {Phe1086} preceding Tyr444
{Tyr1087} interacts directly with residues of ICL1
(Ile160) {ICL3 (Val801)} and residues of ICL4 (Val 908)
{ICL2 (Ile265)}. Moreover, a cation-π interaction is likely
to occur between Phe1086 and Arg262 of ICL2. This last
interaction has no equivalent in the N-terminal NBD.
Propagation of the signal from the residues in ICL1
{ICL3} could then occur through contacts with residues
of ICL4 {ICL2}. In particular Phe163 {Phe804} forms a
hydrophobic cluster with residues of ICL4 (Ile901 and
Phe904) {ICL2 (Leu258 and Ile261)}. Other hydropho-
bic contacts are also formed between Met156 in ICL1
{Leu797 in ICL3} and Val907 in ICL4 {Val264 in ICL2}.
This pathway can be summarized as follows: adenine
interacts either directly or through nearby aromatic resi-
dues of the NBDs with the coupling helix in ICL1 {ICL3}
which itself contacts residues in ICL4 {ICL2}. This trans-
mission strongly implies Asp164 as an important actor.
Asp164 pinpointed by ConSurf is indeed conserved in
MsbA. However it is replaced by an alanine in SAV1866.
A look at the SAV1866 structures does not disclose which
neighboring residue could substitute for Asp164 as a
hydrogen bond maker or which other interaction could
replace the ones observed between Asp164 and either ade-
nine or NBD residues.
Another pathway for signal transmission following ATP
binding could originate from the interaction of the γ
phosphate group with Gln475 {Gln1118} of the Q-loop.
In the same loop, Phe480 {Phe1123} makes hydropho-
bic interactions with Val907 {Val264} located in the mid-
dle of the coupling helix in ICL4 {ICL2}. Interestingly, at
the NBD:TMD interface, Phe480 {Phe1123} shapes an
aromatic cluster with Tyr490 {Tyr1133} and Phe916 of
ICL4 {Phe267 of ICL2}. The equivalent residue of Phe916
in the N-terminal half is substituted by Glu273 in ICL2
but another aromatic residue, Phe267 within ICL2 fills in
the aromatic cluster in the model built using MsbA struc-
ture. In the model based upon SAV1866, the orientation
of Phe267 differs, such that no triple aromatic interaction
is observed with the other two residues (Phe1123 and
Tyr1133). This may be due to the non-conservation in
SAV1866 of the aromaticity at that position (Figure 1).
Deletion of Tyr490 is known to induce defective or no
expression of P-gp[84] and the deletion of the equivalent
residue of Tyr490 in CFTR, Phe508, is the major cystic
fibrosis causing mutation[85]. Remarkably an equivalent
aromatic cluster was identified in a 3D model of CFTR and
its functional importance was reported[46]. In some mod-
els an electrostatic interaction was also observed between
Glu476 of the Q-loop {Glu1119} and Arg905 {Arg262}
in ICL4.
Interestingly Phe480 {Phe1123} of the Q-loop is also pre-
ceded by a conserved leucine, which interacts with resi-BMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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dues of the ABC signature: Leu531 and Ile539 {Leu1176
and Ile1184} which close the ATP binding pocket of the
other NBD.
The second pathway can be summarized as follows: ATP
phosphates interact with residues of the Q-loop which
itself contacts residues of the coupling helix in ICL4
{ICL2}. In a more complex way the signal to ICL4 {ICL2}
in one NBD could also originate from the phosphates of
the facing NBD through residues of the ABC signature
which itself contacts the Q-loop.
Both proposed pathways emphasize the importance of
ICL4 {ICL2} and to a lesser extent ICL1 {ICL3} in the
transmission of a signal from the ATP binding pocket. The
ICL4 {ICL2} links the TM segments (either TM4–TM5 or
TM10–TM11) which mediate the hinge binding motion
allowing the transition from the inward to the outward
conformations as suggested by the MsbA structures.
Remarkably it was shown that CFTR mutants located in
the coupling helix in ICL4 displayed a decreased channel
open probability suggesting the importance of dynamic
contacts at these sites for the conformational change to
occur in this protein[46,86,87]. Also mutations in ICL1 of
CFTR were reported to impede transition to the open state
of the protein[88].
Comparison of the MsbA nucleotide-free and nucleotide-
bound structures suggests that ABC exporters undergo
large conformational changes. These structures pinpoint
to a large motion of the portion formed by TM4/ICL2/
TM5 {or TM10/ICL4/TM11} around a hinge defined by
Top: Drug binding site of the closed nucleotide-free model Figure 4
Top: Drug binding site of the closed nucleotide-free model. Tube representation of the transmembrane region of the 
closed nucleotide-free model. The residues experimentally identified to alter drug specificity are represented in balls and sticks: 
H61, G64, L65, Y118, V125, M197, T199, S222, I306, A311, V331, T333, F335, S337, V338, L339, I340, G341, A342, F343, 
Q725, F728, A729, S766, T769, I840, A841, N842, I864, I867, I868, A871, G872, A935, F938, F942, S943, T945, Q946, Y950, 
F951, S952, Y953, F957, L975, F978, V981, V982, F983, G984 and A985. The two red lines indicate the position of the lipid 
polar heads in the cellular membrane. Bottom: One predicted position for each docked ligand. Ligands are depicted in 
purple and the residues experimentally identified to alter their specificity are colored according to their chemical type (carbon 
in cyan; oxygen in red; nitrogen in blue). (a) colchicine, (b) rhodamineB, (c) verapamil and (d) vinblastine.
a b c dBMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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ECL2/ECL3 {or ECL5/ECL6}[19]. We looked at the con-
served residues identified by ConSurf in these potential
hinge regions. The most conserved residues are Leu214,
Thr215 and Leu216 {Leu 857, Thr858 and Leu859}
located at the N-terminal side of TM4 {TM10} and thus
close to the extracellular loop between TM3 and TM4
{TM9 and TM10} (Figure 6). Interestingly it has been pro-
posed that threonine or serine residues can cause local
alterations which may result in significant conformational
changes across transmembrane helices and which may
play a role in transmembrane signaling[89]. Pro223
{Pro866} located further down TM4 {TM10} has also
been identified as a conserved residue with a potential
role. Despite their disruptive nature, proline residues are
statistically well represented in transmembrane helices.
Proline was reported to play an important role in produc-
ing conformational changes essential for receptor signal-
ing and channel gating[90,91].
C
Studies[70,92] demonstrated that several residues in TM6
in particular those located at the two extremes show large
changes in accessibility to covalent modification by male-
imide reagents suggesting that TM6 undergoes significant
conformational changes upon the catalytic cycle. Our
nucleotide-free and -bound models can readily explain
most of these site-directed labeling data. However, instead
of pointing to a large TM6 motion, our models feature
structural changes in TM6 neighborhood caused by the
hinge bending motion of TM4–TM5 pair which swings
away from TM6 and by the shift of TM7.
Discussion and Conclusion
The lack of a high resolution structure for P-gp and the
recently determined X-ray structures of several ABC
exporters trapped in different conditions prompted us to
construct several 3D models of P-gp featuring different
states along its catalytic cycle. Sequence identity and sim-
ilarities, though varying markedly across the protein, as
well as experimental data support that SAV1866 and
MsbA share the same architecture as P-gp.
We present here two nucleotide-bound and two nucle-
otide-free models of P-gp based on four different template
structures. The two nucleotide-bound models which
depict an outward-facing conformation of P-gp are very
Table 2: Drug binding site residues
P o s e 1234567 8
Colchicine Gln946 Gln946 Ile306 Ile306 Ile306 Ile306 Ile306 Leu339
Tyr950 Tyr950 Phe335 Phe335 Phe335 Phe335 Phe335 Gln725
Tyr953 Tyr953 Phe728 Phe728 Leu339 Phe728 Phe728 Phe728
Phe957 Phe957 Phe728 Phe983
Leu975
RhodamineB Leu65 His61 Phe728 Ile306 Ile306 Ile306 Ala311 Gln725
Ile340 Leu65 Tyr950 Phe335 Phe335 Phe728 Phe335 Phe728
Phe343 Val125 Tyr953 Phe728 Phe728 Phe983 Phe728 Phe983
Phe942 Phe938 Phe957 Phe983 Phe983
Tyr950 Leu975
Tyr953
Phe957
Val982
Verapamil Ile306 Ile306 Ile306 Ala311 Leu65 Ile306 Ile306 Leu975
Phe335 Leu339 Phe335 Phe335 Val125 Phe335 Phe335 Thr333
Leu339 Phe343 Phe728 Phe728 Phe942 Leu339 Leu339
Gln725 Gln725 Leu975 Phe345
Phe728 Phe728
Val125 Ile306 Val125 Val125 Leu65 Ile306 Ile306 Phe343
Ile340 Phe335 Leu339 Leu339 Ile340 Thr333 Phe335 Gln725
Phe343 Leu339 Ile340 Ile340 Phe343 Phe335 Leu339 Phe728
Vinblastine Phe942 Ile340 Phe343 Phe343 Phe728 Leu339 Phe343 Ser766
Gln946 Phe343 Phe938 Phe942 Gln946 Ile340 Phe728 Phe983
Val982 Phe728 Phe942 Val982 Phe983 Phe728 Phe983
Phe983 Phe983 Phe983 Phe983 Phe983
Residues found to interact with each of the 8 predicted positions of the four different ligands (see text) docked in the central cavity of the closed 
nucleotide-free structure. The residues experimentally identified to alter the specificity of a particular ligand are reported in bold and underlined.BMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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NBD:TMD communication pathways Figure 5
NBD:TMD communication pathways. For sake of clarity only the residues identified starting from the N-terminal NBD 
are indicated. First pathway: From adenine → directly or through NBD aromatic residues → ICL1 → ICL4. Second pathway: 
From ATP phosphates → directly to Q-loop of the same NBD or through ABC signature from the ATP of the facing NBD to 
the Q-loop → ICL4. The colors of the links between the residues depict the physical nature of their interactions: yellow: 
hydrophobic, magenta: aromatic-aromatic, cyan: hydrogen bond and blue: electrostatic.
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similar and are in good agreement with the 8 Å resolution
EM data obtained on P-gp. The two nucleotide-free mod-
els which both portray an inward-facing conformation
differ markedly by their opening towards the cytoplasm
and by the absence of a NBD:NBD interface in the open
model. EM and ESR data on homologous proteins also
corroborate the occurrence of large conformational
motions upon nucleotide binding.
All four models were carefully analyzed to compare mod-
eled residue-residue distances to those estimated in cross-
linking experimental studies obtained in a range of condi-
tions: in the presence or absence of substrates, nucleotides
and with chemical cross-linkers (see Table 1). Overall the
pattern of distances from all four models agrees with these
experimental data.
A large number of site-directed and scanning mutagenesis
studies have been performed on P-gp to get insight into
the molecular mechanism and to spot the residues essen-
tial for drug binding and translocation, ATP binding and
hydrolysis. We showed here that our models can be used
to rationalize the effects of several mutants in the NBDs,
or at the interface NBD:TMD or within the TMDs.
Almost all residues known to affect the specificity of indi-
vidual substrates strikingly face the inside of a large pore
and are located mainly in the outer membrane leaflet. The
closed nucleotide-free model can accommodate different
ligands of different size. The mode of association
observed for the docked ligands favors the existence of
multiple binding sites within the large central cavity, a fea-
ture supported by several experimental studies. For each
ligand, several positions are found to involve interactions
with residues identified to alter drug binding (see Table
2).
Docking experiments (data not shown) indicate that no
access is large enough to allow the entry of one ATP mol-
ecule into the catalytic site of the nucleotide-bound mod-
els suggesting that these structures should undergo
changes to accommodate their ligands. In both nucle-
otide-free models ATP can enter to reach a site formed by
Walker A and Walker B motifs which are the hallmark of
some ATPases. However in the closed nucleotide-free
structure the site formed by the Walker A and B motifs of
one NBD is protected partially from the solvent by the
other NBD and is likely to harbor only one ATP molecule.
In the open nucleotide-free model two ATP molecules
could possibly bind as each site formed by the Walker
motifs is fully solvent-exposed. In that respect the latter
model agrees with experiments showing that each P-gp
half expressed in cells exhibits basal ATPase activity that
cannot be stimulated by drugs[93]. One cannot however
exclude that this activity could be due to the presence of
homodimers formed by half molecules.
In contrast to the nucleotide-bound structures, both
nucleotide-free models show possible entries for the sub-
strates either laterally from the inner membrane leaflet or
from the cytoplasm. The open nucleotide-free structure
adopts a rather unique shape which discloses an unusual
chamber within the TMD and a large space between the
NBDs. These features are corroborated by quite recent ESR
studies on MsbA. This structure also reveals entries large
enough to allow access of the bulkier ligands of P-gp. The
closed nucleotide-free structure is also sustained by sev-
Residues potentially involved in the hinge bending motion of  TM3–TM4 and TM5–TM6 pairs Figure 6
Residues potentially involved in the hinge bending 
motion of TM3–TM4 and TM5–TM6 pairs. Ribbon rep-
resentation of TM3–TM4 (in blue) and TM5–TM6 (in green). 
The conserved residues identified by ConSurf (see text) with 
a potential role in the hinge conformational change upon 
ATP binding are depicted as red spheres.BMC Structural Biology 2009, 9:3 http://www.biomedcentral.com/1472-6807/9/3
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eral experimental data. It is the only structure to agree
with the Walker A-Walker A cross-linking distance. This
closed nucleotide-free structure could possibly either
occur sequentially along the catalytic cycle after ligands
enter the open nucleotide-free structure or coexist with the
open structure as suggested by the high mobility noted by
ATR-FTIR and NMR for LmrA[60,62]. The outward facing
conformation of the two nucleotide-bound models fea-
tures a central pore open to the extracellular medium that
would allow substrates to escape.
The determination of 3D models at different stages of the
catalytic cycle can help in proposing a role, in particular,
of the residues essential for the transmission of a signal
producing conformational changes or responsible for the
conformational changes themselves. We indeed identified
two potential pathways formed by a chain of interacting
residues which could be involved in the propagation of a
signal upon ATP binding from the catalytic site through-
out to the TMDs. One highlighted a pathway describing
contacts between adenine either directly or through aro-
matic residues with the coupling helix in ICL1 {or ICL3}
which itself interacts with residues of ICL4 {or ICL2}. The
other pathway depicts a chain of interactions starting
from the ATP phosphate groups to ICL4 {or ICL2} by
means of the Q-loop. One of the interaction sites involves
a cluster of aromatic residues including residues of the Q-
loop and of ICL4 or ICL2. Interestingly an equivalent clus-
ter of aromatic residues was detected in CFTR and its role
on the channel gating was revealed. Mutagenesis of only
one glutamine of the Q-loop has been shown to inhibit
the function suggesting that this mutant also affects the
ATP binding/or hydrolysis in the neighboring NBD [59].
In that respect the second pathway may explain this obser-
vation as it incorporates residues which have been sug-
gested to play a role either in the NBD:TMD
communication (residues of the Q-loop) or in the NBD
dimerization (signature motif). It should also be men-
tioned that several pathways either in series or in parallel
could occur to transmit the signal from the active site to
the TMD.
Our models are thus first approximation models and may
constitute a useful starting point for the understanding of
the complete structural picture of P-gp at the different
stages of the catalytic cycle. They may guide further inves-
tigations of the role of residues at the NBD:NBD and
NBD:TMD interfaces.
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